Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 15 | 2024 | 16215 | 1.130 |
Why?
|
| Hemangiosarcoma | 2 | 2023 | 238 | 0.890 |
Why?
|
| Electrons | 1 | 2023 | 188 | 0.780 |
Why?
|
| Triple Negative Breast Neoplasms | 7 | 2024 | 1386 | 0.740 |
Why?
|
| Mammography | 6 | 2024 | 1052 | 0.590 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2021 | 530 | 0.530 |
Why?
|
| Radiology | 1 | 2021 | 426 | 0.530 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 657 | 0.510 |
Why?
|
| Genetic Testing | 1 | 2024 | 1696 | 0.500 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 5776 | 0.350 |
Why?
|
| Neoadjuvant Therapy | 7 | 2024 | 5231 | 0.350 |
Why?
|
| Breast | 4 | 2024 | 1369 | 0.330 |
Why?
|
| Radiopharmaceuticals | 2 | 2023 | 1341 | 0.280 |
Why?
|
| Culturally Competent Care | 1 | 2024 | 50 | 0.230 |
Why?
|
| Mutation | 1 | 2024 | 15912 | 0.220 |
Why?
|
| Penetrance | 1 | 2024 | 134 | 0.220 |
Why?
|
| Cultural Competency | 1 | 2024 | 70 | 0.220 |
Why?
|
| Breast Diseases | 1 | 2024 | 200 | 0.200 |
Why?
|
| Female | 18 | 2024 | 148940 | 0.200 |
Why?
|
| Vascular Neoplasms | 1 | 2023 | 112 | 0.200 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 380 | 0.190 |
Why?
|
| Genes, BRCA2 | 1 | 2024 | 322 | 0.190 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2024 | 293 | 0.190 |
Why?
|
| Hemangioma | 1 | 2023 | 157 | 0.190 |
Why?
|
| Genes, BRCA1 | 1 | 2024 | 397 | 0.190 |
Why?
|
| Carboplatin | 1 | 2024 | 880 | 0.190 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 528 | 0.180 |
Why?
|
| Ultrasonography, Mammary | 2 | 2021 | 387 | 0.180 |
Why?
|
| Carcinoma, Lobular | 1 | 2023 | 616 | 0.170 |
Why?
|
| Radiologists | 1 | 2021 | 178 | 0.170 |
Why?
|
| Fiducial Markers | 1 | 2019 | 95 | 0.160 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2023 | 690 | 0.160 |
Why?
|
| Humans | 20 | 2024 | 270740 | 0.160 |
Why?
|
| Calcinosis | 1 | 2021 | 426 | 0.150 |
Why?
|
| Skin | 1 | 2023 | 1271 | 0.150 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 1059 | 0.140 |
Why?
|
| Paclitaxel | 1 | 2024 | 2101 | 0.140 |
Why?
|
| Postmenopause | 1 | 2019 | 375 | 0.140 |
Why?
|
| Radiography | 1 | 2021 | 1986 | 0.140 |
Why?
|
| ErbB Receptors | 1 | 2024 | 2375 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 1260 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 880 | 0.130 |
Why?
|
| Curriculum | 1 | 2021 | 919 | 0.130 |
Why?
|
| Overweight | 1 | 2019 | 484 | 0.120 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.120 |
Why?
|
| Metformin | 1 | 2019 | 393 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2019 | 1567 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 2197 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.100 |
Why?
|
| Aged | 8 | 2024 | 73333 | 0.100 |
Why?
|
| ROC Curve | 2 | 2024 | 1248 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 5408 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 16689 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2024 | 13414 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 7895 | 0.070 |
Why?
|
| United States | 1 | 2024 | 15861 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2904 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 14012 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2665 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 7783 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 10400 | 0.060 |
Why?
|
| Anisotropy | 1 | 2024 | 181 | 0.060 |
Why?
|
| Nipples | 1 | 2024 | 122 | 0.060 |
Why?
|
| Middle Aged | 7 | 2024 | 90352 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2024 | 39890 | 0.050 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2023 | 139 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2023 | 564 | 0.050 |
Why?
|
| Adult | 6 | 2024 | 82040 | 0.050 |
Why?
|
| Image-Guided Biopsy | 1 | 2023 | 336 | 0.050 |
Why?
|
| Radar | 1 | 2019 | 2 | 0.040 |
Why?
|
| Radio Frequency Identification Device | 1 | 2019 | 4 | 0.040 |
Why?
|
| Stainless Steel | 1 | 2019 | 23 | 0.040 |
Why?
|
| Drug Implants | 1 | 2019 | 52 | 0.040 |
Why?
|
| Magnets | 1 | 2019 | 33 | 0.040 |
Why?
|
| Needles | 1 | 2019 | 108 | 0.040 |
Why?
|
| Foreign-Body Migration | 1 | 2019 | 122 | 0.040 |
Why?
|
| Gamma Rays | 1 | 2019 | 237 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2024 | 33737 | 0.040 |
Why?
|
| Androstadienes | 1 | 2019 | 172 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2019 | 387 | 0.040 |
Why?
|
| Mastectomy | 1 | 2024 | 1553 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2024 | 3145 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 3245 | 0.030 |
Why?
|
| Everolimus | 1 | 2019 | 436 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1032 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 1049 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2019 | 676 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2021 | 1933 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 599 | 0.030 |
Why?
|
| Radiometry | 1 | 2019 | 1020 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 6177 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 2345 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 1604 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2019 | 1229 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 2835 | 0.030 |
Why?
|
| Prognosis | 2 | 2021 | 22505 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 2170 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 1340 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1610 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 2651 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2024 | 12103 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 13006 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12541 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2023 | 10708 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 15218 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 22251 | 0.010 |
Why?
|